In 2023, Cures Within Reach continued funding Dr. Tycel Phillips at City of Hope (after he moved from University of Michigan) to support a Phase II trial combining two oral cancer drugs with an antibody immunotherapy to improve treatments for patients with mantle cell lymphoma, a rare type of non-Hodgkin lymphoma diagnosed in roughly 5,000 new patients each year in the US.

Dr. Phillips is focused on the management and treatment of patients afflicted with lymphoma, and his research is focused on developing clinical trials that test new treatments and treatment combinations for lymphoma with patients as his highest priority.

Dr. Phillips became interested in cancer treatment after seeing some of the side effects firsthand when a close family member of his was diagnosed with and eventually died from cancer. Inspired most by his mother and paternal grandmother, Dr. Phillips’ favorite part of his job is that “even when you don’t realize it, you are making a major impact in the lives of not only your patients, but also of their family and friends.” His goal: to improve tolerance and outcomes in patients with lymphoma.

PROFILE

- Dr. Tycel Phillips is an internationally recognized expert in lymphoma treatment and research
- He is currently a member of the American Society of Hematology Committee on Promoting Diversity and previously served on the Editorial Board of Clinical Lymphoma, Myeloma & Leukemia

CWR FUNDING

- Cures Within Reach is adding funds to this ongoing Phase II clinical trial testing a drug combination to improve patient response in mantle cell lymphoma
- Dr. Phillips won 2nd place at 2020 CureAccelerator Live! for Rare Diseases
- Dr. Phillips and his trial represent three of Cures Within Reach’s communities:
  - Rare Diseases
  - Oncology
  - Diversity, Equity & Inclusion